ClinicalTrials.gg
TerminatedNCT02746263Updated Nov 19, 2019Results posted

Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain

A Phase 4 interventional study of IV acetaminophen and Oral acetaminophen in Acute Pain, Postoperative, sponsored by Mallinckrodt. Terminated at 2 sites in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Mallinckrodt · Phase 4, Interventional, and Treatment

Why this study was terminated
Business decision because enrollment was slower than expected

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 118 studies testing acetaminophen in Pain, Postoperative — 11 open to participants now, 13 under way, 1 of them phase 3. Acetaminophen · Pain, Postoperative.

Enrollment
111th of 118
1 · median 90
Started
2016
with 5 others
Phase 4
53 of 118
9 open now
Registered
48th of 118
by date
Lead sponsor
3 of 118
Mallinckrodt

Among the 118 studies testing acetaminophen in Pain, Postoperative, this one is the 111th largest by enrollment, is one of 6 that started in 2016, is one of 53 in phase 4, and was the 48th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

11 of the 118 studies testing acetaminophen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies testing acetaminophen in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of this study is to compare intravenous (IV) and oral acetaminophen for the treatment of acute moderate to severe pain in combination with standard patient-controlled analgesia (PCA) in adult subjects following total knee replacement.

03

Conditions studied

  • Acute Pain, Postoperative

Browse trials for

Keywords

  • Elective total knee arthroplasty
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be adequately informed and understand the nature and risks of the study and must be able to provide a signature and date on the form.
  2. Subject must be male or females, between 50 and 90 years of age (inclusive) at Screening.
  3. Subject must have a weight range of 50 to 120 kg.
  4. Subject must be in a risk class of I, II, or III.
  5. Subject must have successfully completed an unilateral uncomplicated total knee replacement surgery, able to take oral medication, and report having moderate to severe acute pain as determined by a pain score ≥ 5 from the 11-point Numeric Pain Rating Scale (NPRS) scale during the period of 3 to 6 hours postsurgery.
  6. Female subjects of must have a negative serum pregnancy test at the Screening and day-of-surgery.
  7. Subjects must be able to communicate effectively with study personnel.
  8. Subject must be able and willing to follow all protocol requirements, including operating a PCA device, and study restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Subject is from a vulnerable population, as defined by the Code of Federal Regulations Title 45, Part 46, 1. Section 46.111(b), including but not limited to employees (temporary, part-time, full time, etc.) or a family member of the research staff conducting the study, or of the sponsor, or of the clinical research organization, or of the Institutional Review Board.
  2. Subject has an oxygen saturation of less than 95% while awake on room air.
  3. Subject has a positive test result for , (surface antigen), or virus antibody at Screening.
  4. Subject has used an average of 30 mg oral morphine equivalents or greater, 1 to 2 weeks prior to the day of surgery. Subjects who, in the investigator's opinion are developing opioid tolerance will be excluded.
  5. Subject has a history of any drug allergy, , or intolerance to acetaminophen or morphine or to any of the in the IV or oral formulations used.
  6. Subject has intra- or postoperative complications, which in the view of the investigator, makes the subject unsuitable for the participation of the study.
  7. Subject has received neuraxial (spinal or epidural) opioid injected perioperatively.
  8. Subject has received a local anesthetic, regional, or wound injection or continuous infusion by any route.
  9. Subject has impaired liver function (eg, , alanine aminotransferase, or greater than or equal to 3.0 times the ), active hepatic disease, evidence of liver disease, or other condition (eg, alcoholism, cirrhosis, or hepatitis) that suggests the potential for an increased susceptibility to hepatic toxicity with study drug exposure.
  10. Subject has renal dysfunction or is at risk for renal failure due to volume depletion.
  11. Subject has donated or had significant loss of whole blood (480 mL or more) within 30 days, or plasma within 14 days prior to dosing.
  12. Subject has had any major surgery within 3 months prior to day-of-surgery.
  13. Subject has a history of acute illness within 14 days prior to day-of-surgery.
  14. Subject has participated in another clinical study within 30 days prior to day-of-surgery or plans to participate in another clinical study while concurrently enrolled in this study.
  15. Subject has a history of conditions which might be specifically or require caution to be used during the administration of any drug in the study.
  16. Subject has any other medical, psychiatric and/or social reason for exclusion as determined by the investigator.
  17. Subject has a positive test result for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids [including medical use of marijuana], cocaine, methamphetamine, methadone, or methylenedioxy-methamphetamine) at Screening. Subjects with a positive test result for prescribed drugs may be included in the study at the discretion of the investigator. Subjects with a positive test result for cannabinoids with a prescription for medical marijuana will be excluded from the study, subjects with a prescription for dronabinol (∆-9-tetrahydrocannabinol) may be included at the discretion of the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    IV acetaminophen/Morphine

    IV acetaminophen 1000 mg every 6 hours over 18 hours

    Drug: IV acetaminophen · Drug: Morphine

  • Active comparator
    Oral acetaminophen/Morphine

    Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours

    Drug: Oral acetaminophen · Drug: Morphine

Interventions

06

What researchers measure

Primary outcomes

  1. Pain Intensity on a Numerical Pain Scale (NPS) for 18 Hours

    Participants rate intensity of their pain on a Numerical Pain Scale (NPS) from 0-10, wherein 0=no pain (better) and 10=most intense pain (worse). The highest possible score is 10.

    Time frame: 18 hours

07

Results

Posted Nov 6, 2019
Limitations and caveats
Early termination leading to small number of participants analyzed. The single participant enrolled was in violation of the protocol, leading to unreliable or uninterpretable data. All AEs were listed, but not related to the study drug.

Participant flow

Participant flow — Overall Study
MilestoneIV Acetaminophen/MorphineOral Acetaminophen/Morphine
Started01
Per protocol analysis set00
Completed01
Not completed00

Outcome measures

PrimaryPain Intensity on a Numerical Pain Scale (NPS) for 18 Hours

Participants rate intensity of their pain on a Numerical Pain Scale (NPS) from 0-10, wherein 0=no pain (better) and 10=most intense pain (worse). The highest possible score is 10.

Time frame:
18 hours

No measurements were reported for this outcome.

Adverse events

Collected over 9 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Acetaminophen/Morphine———
Oral Acetaminophen/Morphine0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventIV Acetaminophen/MorphineOral Acetaminophen/Morphine
Acute blood loss anemiaBlood and lymphatic system disorders—1/1
Diffuse bronchial wall thickeningRespiratory, thoracic and mediastinal disorders—1/1
Intermittent thrombocytopeniaBlood and lymphatic system disorders—1/1
Intermittent leucocytosisBlood and lymphatic system disorders—1/1
Persistent sinus tachycardiaCardiac disorders—1/1
Postoperative painGeneral disorders—1/1
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders—1/1
Stress hyperglycemiaEndocrine disorders—1/1
Suspicion of adrenal insufficiencyEndocrine disorders—1/1

Baseline characteristics

Per Protocol Analysis Set - The single participant enrolled was in violation of the protocol, leading to unreliable or uninterpretable data.

Age, Categorical
Age, CategoricalIV Acetaminophen/MorphineOral Acetaminophen/MorphineTotal
<=18 years———
Between 18 and 65 years———
>=65 years———
Sex: Female, Male
Sex: Female, MaleIV Acetaminophen/MorphineOral Acetaminophen/MorphineTotal
Female———
Male———
Region of Enrollment
Region of Enrollment(participants)IV Acetaminophen/MorphineOral Acetaminophen/MorphineTotal
08

Study locations

2 sites
  • Pensacola Research Consultants
    Pensacola, Florida 32503, United States
  • The Ohio State University, Wexner Medical Center
    Columbus, Ohio 43210, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in May 2016, 0 months.

Results were first posted in Nov 2019, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2016
First posted
Apr 21, 2016
StartActual
Apr 27, 2016
Primary completionActual
May 5, 2016
CompletionActual
May 5, 2016
Results first posted
Nov 6, 2019
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02746263
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Apr 21, 2016
Start date
Apr 27, 2016
Primary completion
May 5, 2016
Completion
May 5, 2016
Results posted
Nov 6, 2019
Last update
Nov 19, 2019

Study contacts

Medical Affairs
study director · Mallinckrodt

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion